Regarding other combinations between anti-PD-1 and anti-VEGF, the phase II/III ORIENT-32 trial (NCT03794440) is assessing the safety, tolerability and effectiveness of sintilimab in combination with IBI305 (anti-VEGF monoclonal antibody, bevacizumab biosimilar) in patients with HCC as the first-line treatment compared with sorafenib (estimated end date: December 2022). This evidence concerns the gene VEGFA and hepatocellular carcinoma.